We have the ability to specifically edit a cell surface receptor to completely prevent antibody binding while keeping the receptor fully functional. Instead of removing a target entirely, this type of epitope editing has the potential to allow the shielding of any cell surface receptor, thereby enabling a much broader application of our technology.
Recent Posts
- Cimeio Therapeutics Therapy Platform Featured in Forbes Article
- Selective haematological cancer eradication with preserved haematopoiesis
- Cimeio Therapeutics Announces Publication in Nature Demonstrating That CD45 ADC and Shielded HSCs Represent a Potentially Universal Therapy for Blood Cancers
- Molecular shielding of CD52 retains expression, anti-phagocytic ‘don’t eat me’ function and protects from Alemtuzumab-mediated depletion
- Cimeio Therapeutics Presents Data for its CD52 Shielding Variant at ASGCT
Recent Comments
No comments to show.